New drug cocktail shows promise for relapsed myeloma
NCT ID NCT04191616
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 study tested a combination of three drugs—carfilzomib, pomalidomide, and dexamethasone—in 54 adults whose multiple myeloma had come back after one or two prior treatments. The goal was to see how many patients responded to the therapy. The study is complete, and results help understand if this combo is effective and safe for this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carfilzomib, pomalidomide, and dexamethasone (a three-drug combination)
What this could lead to
If successful, this combination could offer a new treatment option for patients whose multiple myeloma has returned after earlier therapies.
What could go wrong
This is a small, early-phase study (54 participants) with no comparison group, so results may not apply broadly. Side effects from the drugs can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aalborg Universitetshospital
Aalborg, 9000, Denmark
-
Aarhus Universitetshospital
Aarhus N, 8200, Denmark
-
Affiliated Oncologists, LLC
Chicago Ridge, Illinois, 60415, United States
-
Alexandra Hospital
Athens, 11528, Greece
-
Asklepios Klinik Altona
Hamburg, 22763, Germany
-
Azienda Ospedaliera Citta della Salute e della Scienza di Torino Ospedale Molinette
Torino, 10126, Italy
-
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
Ancona, 60126, Italy
-
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, 25123, Italy
-
Azienda Unita Sanitaria Locale LE Presidio Ospedaliero Vito Fazzi Polo Oncologico Giovanni Paolo II
Lecce, 73100, Italy
-
Baylor Charles A Sammons Cancer Center at Dallas
Dallas, Texas, 75246, United States
-
Blue Ridge Cancer Care
Roanoke, Virginia, 24014, United States
-
CHU Grenoble Alpes
Grenoble, 38043, France
-
Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez
Lille, 59037, France
-
Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut Lévêque
Pessac, 33604, France
-
Centre Hospitalier Universitaire de Nantes
Nantes, 44093, France
-
Centre Hospitalier de Saint Quentin
Saint-Quentin, 02321, France
-
Clinique Sainte Anne
Strasbourg, 67000, France
-
General Hospital Evangelismos
Athens, 10676, Greece
-
General Hospital of Thessaloniki Georgios Papanikolaou
Thessaloniki, 57010, Greece
-
General University Hospital of Patras Panagia i Voithia
Pátrai, 26504, Greece
-
Hospital Clinic i Provincial de Barcelona
Barcelona, Catalonia, 08036, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, Castille and León, 37007, Spain
-
Hospital Universitari Germans Trias i Pujol
Badalona, Catalonia, 08916, Spain
-
Hospital Universitari i Politecnic La Fe
Valencia, Valencia, 46026, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, 31059, France
-
Klinikum Chemnitz gGmbH
Chemnitz, 09113, Germany
-
Minnesota Oncology Hematology PA
Saint Paul, Minnesota, 55102, United States
-
North Estonia Medical Centre
Tallinn, 13419, Estonia
-
Oncology Hematology Care Incorporated
Cincinnati, Ohio, 45236, United States
-
Policlinico Universitario Agostino Gemelli
Roma, 00168, Italy
-
Rocky Mountain Cancer Centers Denver Midtown
Denver, Colorado, 80218, United States
-
Sjaellands Universitetshospital
Roskilde, 4000, Denmark
-
Texas Oncology - Austin Midtown
Austin, Texas, 78705, United States
-
Texas Oncology, Fort Worth
Fort Worth, Texas, 76104, United States
-
Texas Oncology- Tyler
Tyler, Texas, 75702, United States
-
Theagenion Cancer Hospital of Thessaloniki
Thessaloniki, 54007, Greece
-
US Oncology Research Investigational Products Center
Austin, Texas, 78705, United States
-
United States Oncology Regulatory Affairs Corporate Office
Austin, Texas, 78705, United States
-
Universitatsklinikum Tubingen
Tübingen, 72076, Germany
-
University General Hospital of Evros-Alexandroupolis District
Alexandroupoli, 68100, Greece
-
University Hospital of Ioannina
Ioannina, 45500, Greece
-
University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
-
Universitätsklinikum Münster
Münster, 48149, Germany
-
Vejle Sygehus
Vejle, 7100, Denmark
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States